Upcoming event

Tags

[68Ga]Ga-DPI-4452 PET/CT, 3D reconstruction, adjuvant pembrolizumab, advanced RCC, Article of the Month, Artificial intelligence, ASCO GU22, ASCO21, AUA21, augmented reality, belzutifan, biomarkers, Cabozantinib, CAIN trial, Carcinoma, CARE1 trial, ccRCC, CheckMate-214, CheckMate-9ER, Checkpoint Inhibitor, Chronic kidney disease, clampless surgery, clear cell renal cell carcinoma, Cryosurgery, cystic masses, diagnostics, durvalumab, EAU, EAU21, EAU22, EMUC2026, EMUC21, EMUC22, enucleoresection, ERUS 2026, ERUS22, ESMO21, ESMO25, expert interview, first-line, first-line treatment, Frail patient​, Glomerular filtration rate, Guidelines, histology, histotripsy, imaging, IMDC risk model, immunotherapy, International Metastatic Renal Cell Carcinoma Database Consortium, intraoperative cyst rupture, intraoperative ultrasound, Kidney cancer, kidney-preserving, Laparoscopy, lenvatinib, localised renal cell carcinoma, Lymph node metastases, Lymph nodes, Metastasectomy, metastatic clear-cell renal cell carcinoma, metastatic disease, metastatic RCC, MK-1308A, Mortality, mRCC, neoadjuvant immunotherapy, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, oligometastatic renal cell carcinoma, omRCC, Overall survival, papillary tumour, Partial nephrectomy, patient reported outcomes, PD-L1+, PE-PE trial, pembrolizumab, precision therapy, Prognostication, quality of life, Radical nephrectomy, Radical surgery, RAMPART trial, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, resected renal cell carcinoma, risk stratification, robot-assisted partial nephrectomy, Robotic, robotic partial nephrectomy, Robotic prostatectomy, Robotic surgery, selective clamping, stereotactic body radiation therapy, Survival outcome, Suture, sutureless partial nephrectomy, Targeted therapies, TKIs, Treatment response, tumour enucleation, tumour genomics, tumour pseudocapsule rupture, tyrosine kinase inhibitors, Urological surgery, UROonco2025, UROonco24, UROonco25, UROwebinar, Webinar, zero-ischaemia surgery
Show all

Perioperative pembrolizumab plus metastasis-directed therapy versus MDT alone in patients with oligometastatic renal cell carcinoma: The randomized phase II PE-PE trial

ESMO26, October 2026

Patient reported outcomes in resected renal cell carcinoma: Adjuvant durvalumab versus active monitoring in the RAMPART trial

ESMO26, October 2026

Feasibility and reproducibility of PD-L1 assessment within CARE1: A phase III, randomized, biomarker-driven pragmatic trial to optimize first-line treatment in patients with metastatic clear-cell renal cell carcinoma

ESMO26, October 2026

Diagnostic and staging performance of CAIX-targeted [68Ga]Ga-DPI-4452 PET/CT in clear cell renal cell carcinoma: A prospective trial

ESMO26, October 2026

First-line pembrolizumab + lenvatinib + belzutifan or MK-1308A + lenvatinib in advanced RCC: Randomized open-label phase 3 LITESPARK-012 study

ESMO26, October 2026

Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era

The LANCET Oncology, September 2026

Adjuvant pembrolizumab plus belzutifan for renal-cell carcinoma

The New England Journal of Medicine, July 2026

Management of lymph node–positive renal cell carcinoma: Updated recommendations from the European Association of Urology renal cell carcinoma guidelines panel

European Urology, May 2026

What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group

World Journal of Urology, June 2026

Sutureless purely off-clamp robotic partial nephrectomy: Evidence from a randomized controlled noninferiority trial

European Urology, May 2026

Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials

THE LANCET Oncology, June 2026

Decision regret and toxicity perception following adjuvant pembrolizumab in renal cell carcinoma

ASCO2026

Next